7 results about "Obsessive compulsive" patented technology

The present invention relates to a mental disease prediction and diagnosis classification apparatus by means of a natural language expression and a method therefor. According to the present invention, the mental disease prediction and diagnosis classification apparatus comprises: an input unit that receives, as an input from a medical personnel terminal, mental disease natural language expression information of a patient to be diagnosed; a preprocessing unit that tokenizes the mental disease natural language expression information by using a natural language processing (NLP) algorithm; and a disease prediction unit that inputs the tokenized mental disease natural language expression information into a pre-built diagnosis classification model to classify the corresponding patient to be diagnosed as having any one mental disease from among a generalized anxiety disorder, a panic disorder, a post-traumatic stress disorder, obsessive-compulsive thought or rumination, a remarkable obsessive-compulsive behavior, a social phobia, a specific phobia, agoraphobia, an adjustment disorder, an acute stress response, and a mixed obsessive-compulsive thought and behavior.

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and / or solvate thereof. The invention also relates to the use of the compounds of formula (I) as a medicament, in particular for the prevention or treatment of obsessive-compulsive disorder and related behaviors, including addiction, obsessive-compulsive disorder and dietary disorder, and neurodegenerative diseases, such as Parkinson's disease or Alzheimer's disease.

The invention involves the use of formulations of allosteric modulators of primarily 5ht2 / 5ht1, glutamate or SERT serotonin transporter, but also those of: 5ht1a / b / c / d, 5ht2a / b / c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors / systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat or reduce symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), bipolar disorder, and related disorders / conditions.

The present application relates to a method for treating obsessive-compulsive disorder, comprising: a) identifying one or more specific brain regions exhibiting abnormal activation in a subject; and b) targeting the one or more specific brain regions, inhibiting or disrupting neuronal activity in the brain region(s), or interrupting or blocking neuronal signals in the brain region(s) of the subject.

The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

The present invention discloses a set of marker fecal bacterial genera for diagnosing obsessive-compulsive disorder in children and adolescents, and their applications, belonging to the field of molecular biomedical technology. Based on a comparison and analysis of the intestinal microbiota of patients with obsessive-compulsive disorder and healthy controls, the present invention identifies differential bacterial communities between the two groups. Using high-quality data on the relative abundance of differential bacterial communities between patients with obsessive-compulsive disorder and healthy controls as a training set, the present invention enables risk assessment and early diagnosis of patients with obsessive-compulsive disorder. This approach fills a gap in the early biological diagnosis of the disease, provides medical professionals and patients with more diagnostic and treatment options, and avoids problems such as missed and misdiagnosed diagnoses, thus possessing significant clinical significance.

The present invention provides for methods of treating obsessive-compulsive disorder (OCD) and OCD-related disorders (body dysmorphic disorder, hoarding disorder, trichotillomania (hair-pulling disorder), excoriation (skin-picking) disorder, substance / medication-induced obsessive-compulsive and related disorder, obsessive- compulsive and related disorder due to another medical condition, and other specified and unspecified obsessive-compulsive and related disorders), Tic disorders including Tourette syndrome, autism spectrum disorder (ASD) and glutamate excitotoxicity related disorders including amyotrophic lateral sclerosis (ALS), Parkinson's disease, traumatic brain injury, multiple sclerosis, Huntington's disease, and schizophrenia, comprising the step of administering an effective amount of a histamine type 1 receptor agonist and / or histamine type 3 receptor antagonist, such as betahistine or its pharmaceutically acceptable salts, analogs, metabolites, prodrugs, derivatives, metabolites, co-crystals, modifications, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers.